First human tests begin for new autoimmune disease drug
NCT ID NCT07363590
Summary
This is an early Phase 1 study to test the safety and side effects of a new investigational drug called MK-1045. It will involve a small group of 21 people with either systemic lupus erythematosus or rheumatoid arthritis. The main goal is to find safe dose levels by checking how the body processes the drug and monitoring for any adverse reactions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anima Diepenbeek ( Site 0601)
RECRUITINGDiepenbeek, Limburg, 3590, Belgium
Contact Phone: •••-•••-••••
-
Arensia Exploartory Medicine ( Site 1301)
RECRUITINGTbilisi, 0112, Georgia
Contact Phone: •••-•••-••••
-
PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 1001)
RECRUITINGChisinau, 2025, Moldova
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.